NMNH refers to the reduced form of NMN. Preclinical studies show that NMNH demonstrates a remarkable 10X surge in NAD+ levels.
UthPeak™, EffePharm's pioneering NMNH product, received significant attention during Vitafoods Europe 2024. UthPeak™ has completed rigorous toxicology and efficacy tests, proving its safety and benefits for anti-aging, anti-fatigue, and cardiovascular health.
UthPeak™ is currently conducting a phase I clinical trial, with results expected by the end of 2024. UthPeak™ NMNH finished products are available to purchase on Amazon.
Download the file now to learn more.